Introduction
A new scale based on a statistical approach combining Kurtzke's Expanded Disability Status Scale score (EDSS) with historical databases has been developed [1] . This new scale, the Global Multiple Sclerosis Severity Scale (MSSS), aims to provide a measure for disease severity in an individual patient on a crosssectional basis. This has been achieved by providing a statistically constructed look-up table of disease severity scores for patients with an EDSS between 0 and 9.5 and a disease duration between 1 and 30 years. This scale is potentially superior to the non-linear EDSS for statistical evaluations, as it combines EDSS and disease duration in one variable that is normally distributed.
Biomarkers for axonal degeneration, such as neurofilaments, and glial scar tissue, such as glial fibrillary acidic protein (GFAP), have previously been related to disability and prognosis [2 Á/6]. There is supporting evidence from animal and cell-culture work that levels of phosphorylated neurofilaments correlate with the loss of axons and function [7 Á/9] .
Here we investigate for the first time 1) whether the newly developed Global MSSS correlates with biomarkers for axonal degeneration (neurofilaments), glial activation (S100B) and astrogliosis (GFAP), and 2) whether these biomarker levels are higher in those patients with more severe disease as defined by the Global MSSS.
Patients and methods
Data from a previously published cohort of 29 patients with clinically definite MS in whom a three-year follow-up cerebrospinal fluid (CSF) sample was available were reanalysed [10] . The demographic data, representing the current disease course, are summarized in the result section. All analyses were based on this follow-up visit.
The phosphorylated neurofilament heavy chain (NfH SM135 ), the hyperphosphorylated neurofilament heavy chain (NfH SM134 ), glial fibrillary acidic protein (GFAP SM126 ), S100B and ferritin were quantified as described [3, 10] . The phosphoform ratio (ratio0(NfH SMI34 =NfH SMI35 ))10) was used to estimate the degree of phosphorylation, with higher values indicating a higher degree of NfH phosphorylation. Samples of CSF were obtained by routine lumbar puncture. Aliquots of CSF were stored at (/708C until assayed.
The EDSS was recorded as described [11] , the progression index was calculated as the ratio of the EDSS to disease duration and the Global MSSS was taken from figure 3 from the paper by Roxburgh et al [1] . The progression index was calculated as the EDSS divided by the disease duration.
Data analysis
The linear relationship between continuous variables was evaluated using the Spearman correlation coefficient. We were interested in testing whether previously reported correlations of biomarkers with disability scales (NfH SM135 , GFAP and S100B [2, 3] ) would be repeated for the MSSS. The Bonferroni corrected level of significance ( Â/ 0/0.05) for these three comparisons calculates to P 5/0.016. The nonparametric Kruskal Á/Wallis test was used to compare CSF biomarker levels between patients with mild disease course versus those with a severe disease course according to a previously used cut-off value of an MSSS of 4.8 [12] . All comparisons were made using SAS software (version 8.2).
Results
There were 14 female and 15 male patients with a median age of 46.3 (range 28.5 Á/64.8) years, a median disease duration of 13 (range 3.1 Á/27.6) years and a median relapse-free interval of 24 (range 0.7 Á/270.5) months.
The results for the CSF axonal and glial biomarker levels are summarized in Table 1 . Patients with a more severe disease course had an 8-fold higher NfH phosphoform ratio (7.3 versus 0.9, P 0/0.033), indicating a higher degree of NfH phosphorylation in these patients (Table 1 ). In contrast, the estimation of disease severity based on the EDSS alone using our previously published cut-off limit 3 of 6.5 did not reveal such a difference (data not shown).
The CSF NfH SM135 levels correlated with the MSSS (R0/0.44, P0/0.016, Figure 1 ). No such correlation was found for either CSF GFAP or CSF S100B levels with the MSSS (P0/0.81, P0/0.39, respectively).
The Global MSSS correlated with the progression index (R0/0.8, P B/0.0001). However, when we repeated the above analyses using the progression index instead of the Global MSSS, we were not able to show any of the above correlations, nor was there a difference between disease severity groups (data now shown). 
Discussion
The finding of a significant, 8-fold increased degree of NfH phosphorylation, but not of NfH SM135 and NfH SM134 alone, in patients with a more severe disease course on the Global MSSS is interesting. There is a body of evidence from the dementia and motoneuron literature for an increase of NfH phosphorylation (reviewed in Ref. [2] ). Using a different approach we have previously demonstrated that NfH phosphorylation may increase during the progressive phase of MS [10] . Our previous results were based on the classification of MS patients into those with a relapsing Á/remitting (RR) and those with a secondary or primary progressive (SP/PP) disease course [13] . The more convincing finding of an 8-fold difference using the MSSS [1] versus an approximately 2-fold difference using the traditional classification [13] suggests that disease severity and NfH phosphorylation may be related and independent of the clinical phenotype (ie, RR versus SP/PP).
The finding that the strength of the correlation between the CSF NfH SM135 was marginally better with the EDSS (R0/0.54) (see Ref. [10] ) compared to the Global MSSS (R0/0.44) in this analysis can be explained by comparing figure 1 with figure 2A in Ref. [10] . One patient had CSF NfH SM135 levels of 402 pg/mL, an EDSS of 4 and a disease duration of 21.8 years corresponding to a Global MSSS of 2.53. This patient appears as the outlier in figure  1 . Based on other studies on relapsing MS (reviewed in Ref. [2] ), one could argue that the CSF NfH SM135 levels are related to relapses, but we do not believe this to be the case as the last relapse was 72.9 months ago, and CSF neurofilament levels are known to plateau out within three months of a relapse [6] . It is of note that a number of patients with severe disease, ie, a high MSSS, had non-detectable CSF NfH SM135 levels. One possible explanation is that axonal degeneration had already occurred a long time ago and biochemical evidence for the damage had been washed out of the CSF. Another possibility is that these patients may have suffered predominantly from cortical damage, which may not necessarily have been reflected in lumbar CSF, because of the CSF flow dynamics.
We were not able to demonstrate a correlation between the MSSS and the glial biomarkers GFAP and S100B. This finding contrasts with previous reports which showed a correlation between disability scales and CSF GFAP levels [3 Á/5] . The reason for this is likely to be similar to the arguments made above for non-detectable CSF NfH SM135 levels.
The authors of the Global MSSS highlighted that the difficulty in assessing disability is partly caused by the random damage to more or less relevant anatomical pathways [1] . Some of this damage will be caused by demyelination and conduction block, which may resolve. It seems plausible to assume that the occasional functional recovery, even after a structural deficit (ie, definite axonal loss), may at least in part be due to central adaptation or neuronal plasticity.
In conclusion the Global MSSS appears to be a statistically more powerful tool for comparing overall disease severity than the progression index, and should be evaluated alongside the EDSS in the future studies needed to validate the biomarker concept in MS.
